Clinical Trials Logo

Filter by:
NCT ID: NCT05360303 Completed - Clinical trials for Thoracic Outlet Syndrome

Electromyography in Thoracic Outlet Syndrome

ENMG-AFC
Start date: November 9, 2022
Phase:
Study type: Observational

Record the ENMG data carried out systematically in patients treated by rehabilitation for thoracic outlet syndrome in order to assess their characteristics and judge the relevance of these data in the context of the diagnosis and their possible modifications following the rehabilitation treatment.

NCT ID: NCT05357755 Completed - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

SUMMIT
Start date: June 13, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT05357729 Completed - Clinical trials for Visceral and Digestive Surgery

Safety and Performance Study of the MultiSense® Ambulatory Telemonitoring System for Non-critical Patient Management

TELESENSE
Start date: June 14, 2022
Phase: N/A
Study type: Interventional

In this clinical investigation, the investigators will assess the safety, performances and clinical added value of the MultiSense® ambulatory telemonitoring solution in real-life situations.

NCT ID: NCT05355857 Completed - Brain Diseases Clinical Trials

Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.

ATLATEP
Start date: August 10, 2022
Phase: N/A
Study type: Interventional

With 18F-FDG PET, we have few atlases of normality allowing the realization of objective quantitative analyses. An atlas of normality is a probabilistic atlas of normal FDG uptake from a representative set of brain PET images of healthy subjects. This type of atlas is essential for intra- and inter-individual comparisons. Accurate quantitative analysis of brain 18F-FDG PET images acquired on a hybrid PET system has been shown to require an institutional normal database for statistical analyzes (Akdemir et al., JNM 2017 and Della Rosa et al Neuroinformatics, 2014).

NCT ID: NCT05355259 Completed - Carotid Stenosis Clinical Trials

ACtive Catheterization for EndovaScular TreatmentS

ACCESS
Start date: June 27, 2022
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to evaluate the safety and technical success of the Basecamp Vascular controllable directional GECKO guidewire when used to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.

NCT ID: NCT05353738 Completed - COVID-19 Clinical Trials

Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy

CANNEMUSS
Start date: September 1, 2021
Phase:
Study type: Observational

Des vaccins sont désormais disponibles en France, dont le vaccin Moderna COVID-19 qui est basé sur la technologie des ARNm. La séquence génétique qu'il contient code pour la protéine Spike (S) de l'enveloppe virale, protéine clé de la pénétration du virus dans les cellules qu'il infecte. Le vaccin ARNm est injecté par voie intramusculaire et pénètre dans les fibres musculaires, qui sont des cellules produisant des protéines en très grande quantité en continu, notamment pour la production de myofibrilles impliquées dans la contraction musculaire. Une fois à l'intérieur de la fibre musculaire, l'ARNm vaccinal est traduit par la machinerie de la fibre musculaire permettant une grande quantité de protéine Spike (S) qui sera présentée au système immunitaire provoquant la réponse vaccinale et notamment les anticorps neutralisants anti-S (NAb). Ces NAb anti-S agissent en perturbant l'interaction entre la protéine S du virus et le récepteur ACE2 (Angiotensin-Converting Enzyme 2), qui sert généralement de " passerelle " entre le virus et la cellule. Une campagne de vaccination est actuellement en cours au MAS-YDK avec le vaccin Moderna. Cette population est donc relativement homogène en termes d'amyotrophie, de non exposition au SARS-CoV-2 et de protocole vaccinal.

NCT ID: NCT05353621 Completed - Resilience Clinical Trials

Resilience and Acute Stress in Simulation

SimStress
Start date: May 18, 2022
Phase:
Study type: Observational

The objective is to study an association between the resilience developed by anesthesia professionals and the level of acute stress during a simulation session.

NCT ID: NCT05353608 Completed - COVID-19 Clinical Trials

Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients.

SCINTI-COVID
Start date: April 30, 2021
Phase:
Study type: Observational

A frequent complication of COVID-19 disease is pulmonary embolism (PE). Lung ventilation/perfusion (V/P) scintigraphy is a well-established test for PE diagnosis. The test is interpreted based on the recognition of wedge shaped perfusion mismatched defects. However, the ventilation procedure increases the potential risk of contamination by the aerosol secretion and the expired air. A variety of strategies have been proposed in the nuclear medicine literature regarding performance of lung ventilation scintigraphy in COVID-19 patients with suspected acute PE. However, there is currently no factual data in this specific population to support recommendations to the nuclear medicine community. The aim of this study was to assess the role of ventilation imaging when performing lung scintigraphy for suspected PE in COVID-19 patients.

NCT ID: NCT05353023 Completed - Critical Illness Clinical Trials

Intensive Care Unit Activity in France From the National Database Between 2013 and 2019

ICU_ACTIVITY
Start date: January 1, 2013
Phase:
Study type: Observational

Using data from the French National Uniform Hospital Discharge Database (systematically collecting administrative and medical information related to all hospitalized patients in France for care reimbursement purposes), the present study retrospectively assesses the activity of the French Intensive Care Unit (ICU)(1,594,801 ICU admissions): - In-ICU and in-hospital mortality rates - Length of stay in ICU and hospital - Mortality-associated factors during the study period. - Number of organ failures - Bed occupancy, - Regional variations in previous indicators

NCT ID: NCT05352997 Completed - Infectious Disease Clinical Trials

Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients

SPT BETALACT
Start date: January 1, 2018
Phase:
Study type: Observational

The population of these monocentric and retrospective study includes patients hospitalized in one of the critical care services of Nîmes' community hospital. The objective is to determine the key factors that lead to satisfactory beta-lactams serum concentrations in critically ill patients. Clinical and biological features, as well as risk scores are collected and recorded into an electronic Case Report Form. The primary outcome is to show the main characteristics related to adequate beta-lactams serum concentrations in critically ill inpatients. Secondary outcomes include the key factors related to inadequate beta-lactams serum concentrations in critically ill inpatients, Therapeutic Drug Monitoring (TDM) impact in the achievement of target beta-lactams serum concentration and the correlation between Aminoglycosides and Beta-lactams serum concentrations. Do both antibiotics have similar elimination kinetics ?